

ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ – ΣΤΑΥΡΟΥΛΛΑ ΞΕΝΟΦΩΝΤΟΣ

Προσωπικά Στοιχεία

Ημερομηνία γέννησης: 14/09/1966

Τόπος γέννησης: Λευκωσία, ΚΥΠΡΟΣ

Τηλέφωνα επικοινωνίας: 00357-22392651/627

Ηλεκτρονικό ταχυδρομείο: sxenofon@cing.ac.cy



Εκπαίδευση

1985-1988: University College London, University of London, UK

Department of Biology

BSc Degree in Microbiology

Second Class Honours- Upper Division (2I)

1989-1993: University College London, University of London, UK

Department of Genetics, Human Biochemical Genetics Unit, Medical Research Council

Ph.D. In Human Genetics

Τίτλος διατριβής: Genetic and Physical Mapping in the Terminal Region of Human Chromosome 1p

Επαγγελματική Εμπειρία

1988 - 1989: St. Mary's Hospital, Paddington, London, England

Θέση: Medical Laboratory Science Officer in Diagnostic Haematology

1994 - 1996: Ινστιτούτο Νευρολογίας & Γενετικής Κύπρου

Molecular Genetics Department C

Θέση: Μεταδιδακτορική ερευνήτρια

Ερευνητικό Πρόγραμμα: Genetics of Polycystic Kidney Disease (PKD) 1 and 2

1997 – Μέχρι σήμερα

Ινστιτούτο Νευρολογίας & Γενετικής Κύπρου

Εργαστήριο Δικανικής Γενετικής & Τμήμα Καρδιαγγειακής Γενετικής

Θέση: Scientist

Καθήκοντα στο Τμήμα Καρδιαγγειακής Γενετικής

- **Υπηρεσίες**

Παροχή γενετικών διαγνωστικών υπηρεσιών στον τομέα της καρδιαγγειακής γενετικής όπως Θρομβοφιλία, Οικογενής Υπερχοληστερολαιμία, και στοχευμένη ανίχνευση μεταλλάξεων για μια σειρά από συγγενείς καρδιοπάθειες.

- **Έρευνα**
Μελέτη γενετικών παραγόντων, πρωτεϊνικών και επιγενετικών βιοδεικτών που σχετίζονται με την παθολογία των ανευρυσμάτων για καλύτερη κατανόηση των παθολογικών μηχανισμών.
- **Εκπαίδευση φοιτητών**
Παράδοση διαλέξεων στο μάθημα MG101 Molecular Genetics.
Επίβλεψη και εκπαίδευση φοιτητών για την διεκπεραίωση των ερευνητικών προγραμμάτων.
- **Εκπρόσωπος Προστασίας Δεδομένων του Τμήματος.**
- **Έλεγχος αποτελεσμάτων/εκθέσεις διαγνωστικών δοκιμών.**

Καθήκοντα στο Εργαστήριο Δικανικής Γενετικής

- **Υπεύθυνη ποιότητας.**
- **Έλεγχος αποτελεσμάτων/εκθέσεις διαγνωστικών δοκιμών.**
- **Έρευνα.**

Ειδική Εκπαίδευση: Διαχείριση Συστήματος Ποιότητας & Προστασία Προσωπικών Δεδομένων

- ISO 17025:2005 Quality Management System – November 2007
- ISO 17025:2005 Quality Management System / Quality Manager & Internal Auditor Training for Testing Laboratories – November 2008
- ISO 17025:2005 Quality Management System / Quality Manager & Internal Auditor Training for Testing Laboratories – September 2012
- Internal Auditors of Testing Laboratories based on the ISO190011 & criteria of ISO 17025:2017 - June 14-15, 2018.
- GDPR CING STAFF TRAINING - 19/06/2018
- Risk Assessment for ISO 17025:2017-24-25 January, 2019 Nicosia

Εκπαίδευση Λειτουργίας Εξοπλισμού & Λογισμικών Προγραμμάτων

- ABI 310 Genetic Analyzer – March 1998
- ABI 7700 Sequence Detection System – April 2001
- AB 7500 Sequence Detection System – April 2004
- Sequenom MALDI-TOF Mass Spectrometer – October 2006
- AB 3130xl Genetic Analyzer – November 2006
- QIAGEN BioRobot Universal – May 2011
- Statistical Package for Social Sciences Version 12 (SPSS BSI) – Athens, Greece June & September 2003

Συνέδρια/Σεμινάρια/Παρουσιάσεις

Καρδιαγγειακή Γενετική

- Inaugural Euro Conference of the Eastern Mediterranean Region of the International Biometric Society
Athens, Greece, January 8-10, 2001 (*Oral presentation*)
- 73rd European Atherosclerosis Society Congress
Salzburg, Austria, July 7-10, 2002 (*Poster presentation*)
- Thrombophilia & Venous Thromboembolism: Investigation and Management.

- Limassol, Cyprus, 28th November –3rd December, 2003. (*Oral presentation*)
- 75th European Atherosclerosis Society Congress
Prague, Czech Republic, April 2005. (*Poster presentation*)
- XIV International Symposium on Atherosclerosis
Rome, Italy, June 18-22, 2006. (*Poster presentation*)
- 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases- Prevention and Intervention – Health Policy
Venice Lido, Italy, October 22-25, 2008. (*Poster presentation*)
- Δικανική Γενετική**
- 29th ENFSI DNA Working Group Meeting, Zurich, Switzerland – 25-26 September, 2008
- 30th ENFSI DNA Working Group Meeting, Lisbon, Portugal -23rd-24th April, 2009
- 32nd ENFSI DNA Working Group Meeting, The Hague, The Netherlands – 14th-15th April, 2010
- 34th ENFSI DNA Working Group Meeting, Brussels, Belgium – 7th-8th April, 2011
- 24th World Congress of the International Society of Forensic Genetics - Vienna, Austria, August 29th -September 3rd, 2011
- 35th ENFSI DNA Working Group Meeting, Athens, Greece – 25th-26th October, 2011
- Interpol Meeting on DVI – Limassol, Cyprus - 26th February 2012 (*Oral presentation*)
- Training on Police Investigation Procedures and Techniques - EUROMED POLICE III PROJECT - 8th-9th October 2013 (*Oral presentation*)
- 42nd ENFSI DNA Working Group Meeting - Rome, 18-20th April 2018 (*Oral presentation*)
- 43rd ENFSI DNA Working Group Meeting - Spain, Madrid 8th-10th May 2019
- 44th ENFSI DNA Working Group Meeting - Virtual 9-10th September 2020 (*Invited Oral presentation*)
- 45th ENFSI DNA Working Group Meeting - Virtual 20th April 2021
- 46th ENFSI DNA Working Group Meeting - Virtual 28th-29th September 2021 (*Invited Oral presentation*)
- 47th ENFSI DNA Working Group Meeting – Portugal, Lisbon 28th-30th September 2022 (*Invited Oral presentation*)

Χρηματοδότηση για Έρευνα

- **Ευρωπαϊκά Ανταγωνιστικά Προγράμματα:**
(Co-PI) ISFP-2020-AG-IBA-ENFSI, Monopoly Grant 2020 – €20,000 (Principal Investigator for Cyprus Team) Competency, Education, Research, Testing, Accreditation and Innovation in Forensic Science. Starting Date: January 2022. (CERTAIN-FORS). Work Package 5: Establishment of a Trace DNA Transfer Rate Repository & Bayes Net to Calculate LR_s (ReAct). (Total EU Funding 293,000 for 32 ENFSI DNA EWG participating laboratories).
- **Χρηματοδότηση από εσωτερικά κονδύλια του ΙΝΓΚ:**
 - €49,000 NGS Studies in Cardiovascular Diseases (Co - PI), 2021-2022
 - €25,000 Forensic Genetic Studies (Co - PI), January 2023- December 2023

Επαγγελματικές Επιτροπές

- Active member of the ENFSI Expert DNA Working Group.
- Appointed Quality Manager of The Laboratory of Forensic Genetics by the LabFoG Director (2007).

- Appointed member of the bioethics review committee for biomedical research on human beings and their biological substances by the Cyprus National Bioethics Committee (CNBC) for the following periods:
- 28/11/2008-27/11/2009 (Member)
- 01/12/2011-30/11/2013 (Chairwoman)
- 01/12/2018-30/11/2021 (Member)
- 01/12/2021-30/11/2024 (Member)
- Appointed Sub-Team Leader for the preparation of the Best Practice Manual for DNA Profiling as part of the Monopoly 2018 Funding Programme (AFORE) by the ENFSI DNA Expert Working Group. January 2020 – December 2022
- Elected Co-Chair of the ENFSI DNA Expert Working Group Quality Assurance Sub-Group. (29/09/2021-29/09/2024).
- Secretary of the CING Gender Equality Plan Committee 2022 - 2025

Γνώσεις Η/Υ/Λογισμικών προγραμμάτων

- Proficient in Microsoft Office Word, PowerPoint and Excel
- SPSS V12
- HUGINEXPERT (for Bayesian Networks)

Γλώσσες

- **Απταιστα Αγγλικά & Ελληνικά**

Δημοσιεύσεις

1. **Stavroulla Xenophontos**, Margarita Zachariou, Pavlos Polycarpou, Elena Ioannidou, Vera Kazandjian, Maria Lagou, Anna Michaelidou, George M. Spyrou, Marios A. Cariolou, Leonidas Phylactou. The Cyprus Institute of Neurology and Genetics, an emerging paradigm of a gender egalitarian organisation. PLoS One. 2022 Sep 15;17(9):e0274356. doi: 10.1371/journal.pone.0274356. eCollection 2022.
2. Moutsouri Irene, Keravnou Anna, Manoli Panayiotis, Bertoncini Stefania, Michailidou Kyriaki; Christofi Vasilis, **Xenophontos Stavroulla**, Cariolou, Marios A, Bashiardes Evy. Comparative Y-chromosome analysis among Cypriots in the context of historical events and migrations. PLoS One. 2021; 16(8): e0255140. PMID: 34424929
3. Manoli P, Antoniou A, Bashiardes E, **Xenophontos S**, Photiades M, Stribley V, Mylona M, Demetriou Ch, Cariolou AM (2015). Sex-specific age association with primary DNA transfer. Int J Legal Med. DOI 10.1007/s00414-015-1291-2.
4. **Xenophontos S**, Christofi V, Iosif G, Polycarpou P, Manoli P, Cariolou MA (2014). Internal validation of the QIAamp DNA Investigator kit QIAamp 96 DNA Swab BioRobot kit and the BioRobot Universal System for DNA extraction from reference and crime scene samples. Forensic Science International: Genetics 14: e8-e10.
5. Diakou M, Miltiadous G, Xenophontos SL, Manoli P, Cariolou MA, Elisaf M. Spectrum of LDLR gene mutations, including a novel mutation causing familial hypercholesterolaemia, in North-western Greece (2011). Eur J Intern Med 22(5):0, PMID 21925044.

6. Diakou M, Miltiadous G, **Xenophontos S**, Cariolou M, Heta N, Korita I, Bulou A, Refatllari E, Bairaktari E, Elisaf M (2010). Characterization of low density lipoprotein receptor (LDLR) gene mutations in Albania. *Arch Med Sci. Apr* 30; 6(2):198-200. PMID: 22371747.
7. **Xenophontos Stavroulla**, Hadjivassiliou Marilena, Karagrigoriou Alexandros, Demetriou Nafsika, Miltiadous George, Marcou Ioannis, Elisaf Moses, Mikhailidis Dimitri P, Cariolou Marios A Low HDL Cholesterol, Smoking and IL-13 R130Q Polymorphism are Associated with Myocardial Infarction in Greek Cypriot Males. A Pilot Study. (2008). *Open Cardiovasc Med J*, PMID 18949100.
8. Saunders CJ, September AV, **Xenophontos SL**, Cariolou MA, Anastassiades LC, Noakes TD, Collins M No Association of the ACTN3 gene R577X polymorphism with endurance performance in Ironman Triathlons. *Ann Hum Genet.* (2007) Nov;71 (Pt 6):777-81. PMID: 17627799.
9. Saunders CJ, de Milander L, Hew-Butler T, **Xenophontos SL**, Cariolou MA, Anastassiades LC, Noakes TD, Collins M (2006). Dipsogenic genes associated with weight changes during Ironman Triathlons. *Hum Mol Genet.* Oct 15;15(20):2980-7. Epub 2006 Sep 1.
10. Saunders CJ, **Xenophontos SL**, Cariolou MA, Anastassiades LC, Noakes TD, Collins M (2006). The bradykinin {beta}2 receptor (BDKRB2) and endothelial nitric oxide synthase 3 (NOS3) genes and endurance performance during Ironman Triathlons. *Hum Mol Genet.* Mar 15;15(6):979-87. Epub 2006 Feb 6.
11. Miltiadous G, **Xenophontos S**, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M (2005). Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. *Pharmacogenet Genomics.* Apr;15(4):219-25.
12. Nicolaides AN, Breddin HK, Carpenter P, Coccheri S, Conard J, De Stefano V, Elkoofy N, Gerotziakas G, Guermazi S, Haas S, Hull R, kalodiki E, Kristof V, Michiels JJ, Myers K, Pineo G, Prandoni P, Romeo G, Samama MM, Simonian S, **Xenophontos S**. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. European Genetics Foundation; Cardiovascular Disease Educational and Research Trust; International Union of Angiology; Mediterranean League on Thromboembolism *Int Angiol.* 2005 Mar;24(1):1-26.
13. Miltiadous G, **Xenophontos S**, Cariolou M, Elisaf M. ACE insertion deletion polymorphisms and effectiveness of statin therapy. *Atherosclerosis.* 2005 Feb;178(2):405.
14. Collins M, **Xenophontos SL**, Cariolou MA, Mokone GG, Hudson DE, Anastasiades L, Noakes TD (2004). The ACE gene and endurance performance during the South African Ironman Triathlons. *Med Sci Sports Exerc.* Aug;36(8):1314-20.
15. Kakafika AI, **Xenofontos S**, Tsimihodimos V, Tambaki AP, Lourida ES, Kalaitzidis R, Cariolou MA, Elisaf M, Tselepis AD (2003). The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. *J Lipid Res.* Oct;44(10):1919-26. Epub 2003 Jul 16.
16. **Xenophontos SL**, Hadjivassiliou M, Ayrton N, Karagrigoriou A, Pantzaris M, Nicolaides AN, Cariolou MA (2002). Spectrum and prevalence of prothrombotic single nucleotide polymorphism profiles in the Greek Cypriot population. *Int Angiol.* Dec;21(4):322-9.

17. Miltiadous G, Elisaf M, Bairaktari H, **Xenophontos SL**, Manoli P, Cariolou MA (2001). Characterization and geographic distribution of the low density lipoprotein receptor (LDLR) gene mutations in northwestern Greece. *Hum Mutat.* May;17(5):432-3.
18. Miltiadous G, Elisaf M, **Xenophontos S**, Manoli P, Cariolou MA (2000). Segregation of a novel LDLR gene mutation (I430T) with familial hypercholesterolaemia in a Greek pedigree. *Hum Mutat.* Sep;16(3):277.
19. **Xenophontos SL**, Pierides A, Demetriou K, Avraamides P, Manoli P, Ayrton N, Skordis N, Anastasiadou V, Miltiadous G, Cariolou MA (2000). Geographical clustering of low density lipoprotein receptor gene mutations (C292X; Q363X; D365E & C660X) in Cyprus. *Hum Mutat.* Apr;15(4):380.
20. **Xenophontos S**, Constantinides R, Hayashi T, Mochizuki T, Somlo S, Pierides A, Deltas CC (1997). A translation frameshift mutation induced by a cytosine insertion in the polycystic kidney disease 2 gene (PKD2). *Hum Mol Genet.* Jun;6(6):949-52.
21. Constantinides R, **Xenophontos S**, Neophytou P, Nomura S, Pierides A, Deltas CC (1997). New amino acid polymorphism, Ala/Val4058, in exon 45 of the polycystic kidney disease 1 gene: evolution of alleles. *Hum Genet.* May;99(5):644-7.
22. Mochizuki T, Wu G, Hayashi T, **Xenophontos SL**, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, Pierides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJ, Somlo S (1996). PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. *Science.* May 31;272(5266):1339-42.